https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-04-09 / Cell Rep Med 2024 Apr;:101516
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-04-09 / Cell Rep Med 2024 Apr;:1015162024-04-09 00:00:002024-04-09 00:00:00Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-02-10 / J Med Case Rep 2024 Feb;18(1):88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-02-10 / J Med Case Rep 2024 Feb;18(1):882024-02-10 00:00:002024-02-10 00:00:00Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-06 / Cureus 2023 Nov;15(11):e48412
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-06 / Cureus 2023 Nov;15(11):e484122023-11-06 00:00:002023-11-06 00:00:00Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e1099
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e10992023-11-01 00:00:002023-11-01 00:00:00The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-10-19 / Cureus 2023 Oct;15(10):e47320
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-10-19 / Cureus 2023 Oct;15(10):e473202023-10-19 00:00:002023-10-19 00:00:00WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-10-04 / Cells 2023 Oct;12(19)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-10-04 / Cells 2023 Oct;12(19)2023-10-04 00:00:002023-10-04 00:00:00Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-01 / J Med Virol 2023 Feb;95(2):e28554
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-01 / J Med Virol 2023 Feb;95(2):e285542023-02-01 00:00:002023-02-01 00:00:00Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-01 / Integr Cancer Ther 2022;21:15347354221083968
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-01 / Integr Cancer Ther 2022;21:153473542210839682022-01-01 00:00:002023-03-22 14:40:49A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-24 / ESMO Open 2022 Feb;7(1):100334
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-24 / ESMO Open 2022 Feb;7(1):1003342021-12-24 00:00:002023-03-22 14:40:50Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-11-24 / World J Clin Oncol 2021 Nov;12(11):966-982
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-11-24 / World J Clin Oncol 2021 Nov;12(11):966-9822021-11-24 00:00:002023-03-22 14:41:40Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
